Plain-English translation of NCT06642025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called EX02 CAR-T therapy for people with acute myeloid leukemia (a type of blood cancer) that has either stopped responding to standard chemotherapy or has returned after treatment. The therapy works by taking your own immune cells, engineering them in a laboratory to recognize and attack leukemia cells, and then putting them back into your body. This is an early-stage trial with a small group of patients to see if the medication is safe and effective.
Many people with acute myeloid leukemia do not respond well to standard chemotherapy, or their cancer returns after treatment. This trial exists because doctors need new options for these patients, and this medication represents a promising approach using engineered immune cells to fight the cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have a screening visit to confirm you are eligible. Then you will undergo leukapheresis—a procedure where blood is drawn, immune cells are collected, and the rest of your blood is returned to you. Your cells will be taken to a laboratory to be engineered into the new treatment. While your cells are being prepared, you will receive chemotherapy (cyclophosphamide and fludarabine) to prepare your body. Once your engineered cells are ready, you will receive them back through an intravenous infusion. After that, you will have regular follow-up visits to monitor how you are responding and check for any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China